To further explore the concept that NRF2 status and function in the cell could be a contributing determinant and basis of HER4 receptor expression and cellular sensitivity and response of some cancers to LAP and/or ERL, we developed an ERL resistant PEO1 cell line using a previously described approach [43–45]. The gene discussed is CEBPB; the disease is cancer.